A significant reduction in the incidence of major cardiovascular events (MACE) has been observed in patients with type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 receptor agonists (GLP-1RA), suggesting the possibility of cardioprotective actions for some molecules of the class [1, 2]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.